Detection of single nucleotide variants in circulating tumor DNA of patients with metastatic castration resistant prostate cancer

Study of Cell-Free DNA in Prostate Cancer

Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.

Detailed description of study

The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: prostate cancer
  • Age: 100 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 1706003129 (IUSCC-0634)

This study investigates cell-free DNA in patients with metastatic castration-resistant prostate cancer. Metastatic castration-resistant prostate cancer is a type of prostate cancer that continues to grow and spread even when the amount of testosterone in the body is reduced to very low levels. The study aims to understand how cell-free DNA, which are small pieces of DNA found in the blood, can be used to track the cancer's response to treatment.

Participants will receive therapy with either an investigational medication or a placebo. The study will involve regular blood tests to measure cell-free DNA levels. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.

  • Who can participate: Men aged 18 and older with metastatic castration-resistant prostate cancer who are eligible for treatment with abiraterone or enzalutamide may participate.
  • Study details: Participants will be assigned to receive either an investigational medication or a placebo. Blood samples will be collected to measure cell-free DNA levels. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here